Olink Holding AB (publ) (OLK)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Olink Holding AB (publ) (OLK) trades at $26.08 with AI Score 58/100 (Grade B). Olink Holding AB (publ) provides products and services for life science research, focusing on protein biomarker discovery. Market cap: $3.24B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for OLK: OLK does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OLK against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
OLK: 1/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Olink Holding AB (publ) (OLK) Healthcare & Pipeline Overview
Olink Holding AB specializes in innovative protein biomarker discovery solutions, offering a range of products and services like Olink Explore and Olink Target, catering to academic, government, and biopharmaceutical institutions. The company's focus on life science research positions it within the growing diagnostics and research sector.
What Is the Investment Thesis for OLK?
Olink Holding AB presents a compelling investment case within the life science research sector. The company's innovative protein biomarker discovery solutions cater to a growing demand for advanced research tools. With a market capitalization of $3.24B, Olink's growth is driven by its expanding product portfolio, including Olink Explore, Target, and Focus platforms. Key catalysts include ongoing collaborations with academic and biopharmaceutical institutions and expansion into new geographic markets. However, the company's negative P/E ratio of -102.15 and a negative profit margin of -18.6% indicate potential financial risks. The company's beta of 0.52 suggests lower volatility compared to the market. Successful execution of its growth strategies and improved profitability are crucial for long-term value creation.
Based on FMP financials and quantitative analysis
OLK Key Highlights
- Market capitalization of $3.24B, reflecting investor confidence in Olink's market position.
- Gross margin of 58.2%, indicating strong pricing power and efficient cost management.
- Negative P/E ratio of -102.15, suggesting the company is currently unprofitable but has growth potential.
- Profit margin of -18.6%, highlighting the need for improved operational efficiency.
- Beta of 0.52, indicating lower volatility compared to the broader market.
Who Are OLK's Competitors?
OLK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMED Amedisys, Inc. | $100.99 | +0.01% | $3.32B | 50 |
| AXNX Axonics, Inc. | $70.98 | +0.00% | $3.63B | 58 |
| CBAY CymaBay Therapeutics | $32.48 | +0.03% | $3.73B | 59 |
| MOR MorphoSys AG | $18.96 | +2.43% | $2.86B | 53 |
| MORF Morphic Holding, Inc. | $56.99 | +0.04% | $2.86B | 44 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OLK's Key Strengths?
- Innovative protein biomarker discovery technology.
- Comprehensive product portfolio.
- Strong brand reputation.
- Direct sales force.
What Are OLK's Weaknesses?
- Negative profit margin.
- High operating expenses.
- Dependence on research grants and funding.
- Limited geographic presence in some regions.
What Could Drive OLK Stock Higher?
- Expansion of Olink Explore platform into new therapeutic areas.
- Strategic partnerships with biopharmaceutical companies for drug discovery.
- Launch of new protein biomarker assays in 2027.
- Geographic expansion into the Asia Pacific region by 2028.
What Are the Key Risks for OLK?
- Negative return on equity (-6.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players in the diagnostics and research industry.
- Technological obsolescence due to rapid advancements in proteomics.
- Negative profit margin and high operating expenses.
- Dependence on research grants and funding, which can be subject to fluctuations.
- Currency risk due to fluctuations in the exchange rate between the U.S. dollar and the Swedish Krona.
What Are the Growth Opportunities for OLK?
- Expansion of Olink Explore Platform: The Olink Explore platform, designed for studying cardiovascular, metabolic, oncology, neurology, and inflammation diseases, represents a significant growth opportunity. The increasing prevalence of these diseases drives demand for advanced research tools. Olink can leverage its platform to capture a larger share of the market, estimated to reach $150 billion by 2028, by expanding its applications and geographic reach. Timeline: Ongoing.
- Strategic Partnerships with Biopharmaceutical Companies: Collaborating with biopharmaceutical companies to integrate Olink's technology into drug discovery and development processes presents a substantial growth avenue. These partnerships can drive revenue through licensing agreements and service contracts. The biopharmaceutical market is projected to reach $2 trillion by 2027, offering significant opportunities for Olink. Timeline: Ongoing.
- Geographic Expansion into Asia Pacific: Expanding its direct sales force and establishing a stronger presence in the Asia Pacific region can unlock significant growth potential. The region's rapidly growing healthcare market and increasing investments in life science research create a favorable environment for Olink's products and services. The Asia Pacific diagnostics market is expected to reach $50 billion by 2025. Timeline: Upcoming: 2026-2028.
- Development of New Protein Biomarker Assays: Investing in the development of new protein biomarker assays can expand Olink's product portfolio and attract new customers. These assays can target emerging areas of research and address unmet needs in the market. The global biomarker market is projected to reach $60 billion by 2027. Timeline: Ongoing.
- Integration of Artificial Intelligence and Machine Learning: Integrating AI and machine learning technologies into Olink's data analysis and bioinformatics services can enhance the value proposition and attract customers seeking advanced solutions. These technologies can improve data processing, accelerate research, and provide deeper insights. The AI in healthcare market is expected to reach $45 billion by 2028. Timeline: Upcoming: 2027-2029.
What Opportunities Does OLK Have?
- Expansion into new geographic markets.
- Strategic partnerships with biopharmaceutical companies.
- Development of new protein biomarker assays.
- Integration of AI and machine learning technologies.
What Threats Does OLK Face?
- Intense competition.
- Technological obsolescence.
- Regulatory changes.
- Economic downturns.
What Are OLK's Competitive Advantages?
- Proprietary Technology: Olink's proprietary protein biomarker discovery technology provides a competitive advantage.
- Strong Brand Reputation: Olink has established a strong brand reputation in the life science research community.
- Extensive Product Portfolio: The company's comprehensive product portfolio caters to a wide range of research needs.
- Direct Sales Force: Olink's direct sales force enables strong customer relationships and market penetration.
What Does OLK Do?
Olink Holding AB (publ), founded in 2004 and headquartered in Uppsala, Sweden, is a company focused on advancing life science research through innovative protein biomarker discovery solutions. Originally known as Knilo HoldCo AB, the company rebranded to Olink Holding AB (publ) in January 2021. As a subsidiary of Summa Equity Holding AB, Olink provides a comprehensive suite of products and services tailored for academic, government, biopharmaceutical, and biotechnology institutions. Its core offerings include the Olink Explore platform, designed for studying cardiovascular, metabolic, oncology, neurology, and inflammation diseases. Additionally, Olink offers the Target and Focus product lines, which provide custom solutions for researchers focusing on specific proteins or protein signatures. Olink's product portfolio also includes the Olink Signature Q100, a qPCR readout platform, and a range of analysis and bioinformatics services. These services encompass study design consultation, sample preparation, assay execution, data processing, quality control, and the Olink normalized protein expression (NPX) Manager software. Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data, further enhances its service offerings. The company markets its products and services through a direct sales force across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions.
What Products and Services Does OLK Offer?
- Provides Olink Explore platform for studying various diseases.
- Offers Olink Target and Focus product lines for custom protein analysis.
- Develops and markets the Olink Signature Q100 qPCR readout platform.
- Provides study design and consultation services.
- Offers sample preparation and assay execution services.
- Delivers data processing and quality control services.
- Provides bioinformatics services for data analysis.
- Offers Olink NPX Manager software for data management.
How Does OLK Make Money?
- Direct sales of Olink Explore, Target, and Focus product lines.
- Revenue from Olink Signature Q100 qPCR readout platform sales.
- Service fees for study design, sample preparation, and assay execution.
- Subscription fees for Olink NPX Manager software and Olink Insight platform.
What Industry Does OLK Operate In?
Olink Holding AB operates in the rapidly evolving medical diagnostics and research industry. The market is driven by increasing demand for personalized medicine, advancements in proteomics, and growing investments in life science research. Key trends include the adoption of high-throughput technologies and the integration of bioinformatics solutions. Olink competes with companies like AMED, AXNX, CBAY, MOR, and MORF, which offer various diagnostic and research tools. The industry is characterized by intense competition and the need for continuous innovation to maintain a competitive edge.
Who Are OLK's Key Customers?
- Academic institutions conducting life science research.
- Government research organizations.
- Biopharmaceutical companies involved in drug discovery and development.
- Biotechnology companies focused on protein analysis.
Company Profile
Olink Holding AB (publ) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Uppsala, SE. The company is led by CEO Jon Heimer. OLK has traded publicly since 2021.
F-Score 1/9Financial Health
Olink Holding AB (publ)'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 24.07 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -7%Key Financial Metrics
Return on equity for Olink Holding AB (publ) stands at -6.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.0%, the inverse of the P/E and a quick read on earnings relative to price.
OLK Valuation & Market Position
With a $3.24B market cap, Olink Holding AB (publ) sits in the mid-cap segment of the market. Relative to its peer group, OLK's quantitative score of 58/100 is roughly in line with the peer average of 53/100.
FY2026 estForward Outlook
Wall Street analysts project Olink Holding AB (publ) revenue of about $281.7M for fiscal 2026, with EPS near $0.05.
OLK Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Olink's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting Olink's innovative approach to proteomics and its growing market relevance.
- Analysts have noted recent partnerships that could enhance Olink's product offerings, positioning it favorably against competitors.
- The overall biotech sector has shown resilience, and Olink's unique technology may attract increased investor interest.
Bear Case
- Concerns about the sustainability of Olink's revenue growth have surfaced, with some investors questioning the scalability of its business model.
- Bearish sentiment in the community reflects worries over potential regulatory challenges that could impact Olink's operations.
- Recent market developments in the biotech space have led to increased competition, raising doubts about Olink's market share.
- Insider selling has also been reported, which can create uncertainty and lead to negative perceptions among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
OLK Latest News
No recent news available for OLK.
OLK Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OLK.
Price Targets
Wall Street price target analysis for OLK.
OLK MoonshotScore
What does this score mean?
The MoonshotScore rates OLK's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jon Heimer
CEO
Jon Heimer is the CEO of Olink Holding AB (publ). Information regarding his detailed career history, education, and previous roles is not available in the provided data. However, as the CEO, he is responsible for leading the company and overseeing its strategic direction.
Track Record: Information regarding Jon Heimer's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. His role involves managing 707 employees and driving the company's growth in the life science research sector.
Olink Holding AB (publ) ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For Olink Holding AB (publ), as an ADR, it allows U.S. investors to easily invest in the company without the complexities of cross-border transactions. Each ADR represents a specific number of Olink's ordinary shares held by a depositary bank.
- Home Market Ticker: Nasdaq Stockholm, Sweden
- ADR Level: 2
- ADR Ratio: 1:1
OLK Healthcare Stock FAQ
What does Olink Holding AB (publ) do?
Olink Holding AB (publ) specializes in protein biomarker discovery solutions, offering a range of products and services to academic, government, biopharmaceutical, and biotechnology institutions. Its core offerings include the Olink Explore platform, designed for studying various diseases, and the Target and Focus product lines, which provide custom solutions for researchers focusing on specific proteins. The company also offers bioinformatics services and software for data analysis, positioning itself as a key player in advancing life science research.
What are the main risks for OLK?
The main risks for Olink Holding AB (publ) include intense competition from established players in the diagnostics and research industry, technological obsolescence due to rapid advancements in proteomics, and the company's negative profit margin and high operating expenses. Additionally, Olink is dependent on research grants and funding, which can be subject to fluctuations. Currency risk due to fluctuations in the exchange rate between the U.S. dollar and the Swedish Krona also poses a potential risk to investors.
What are the key factors to evaluate for OLK?
Olink Holding AB (publ) (OLK) holds an AI score of 58/100 (moderate). Not financial advice.
How frequently does OLK data refresh on this page?
OLK prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OLK's recent stock price performance?
Olink Holding AB (publ) (OLK) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative protein biomarker discovery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OLK overvalued or undervalued right now?
Valuing Olink Holding AB (publ) (OLK) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OLK?
Before investing in Olink Holding AB (publ) (OLK), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding OLK to a portfolio?
Key strength of Olink Holding AB (publ) (OLK): Innovative protein biomarker discovery technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide further insights.
- CEO background information is limited in the provided data.